Napoleone ferrara biography samples

Napoleone ferrara biography samples Bio Dr. In , Dr. Ferrara: I grew up in a city called Catania, which is in Sicily. Ferrara and his colleagues pioneered the clinical development of an inhibiting antibody against VEGF which opened up a new era of cancer therapy because this new approach focused on choking off the blood supply that tumours need in order to grow and spread.

Napoleone Ferrara

Italian-American molecular biologist

Napoleone Ferrara (born 26 July in Catania) is an Italian-American molecular biologist who joined University of California, San DiegoMoores Cancer Center in after a career in Northern California at the biotechnology giant Genentech, where he pioneered the development of new treatments for angiogenic diseases such as cancer, age-related macular degeneration (AMD), and diabetic retinopathy.[1] At Genentech, he discovered VEGF—and made the first anti-VEGF antibody—which suppresses growth of a variety of tumors.

These findings helped lead to development of the first clinically available angiogenesis inhibitor, bevacizumab (Avastin), which prevents the growth of new blood vessels into a solid tumor and which has become part of standard treatment for a variety of cancers.[citation needed] Ferrara's work led also to the development of ranibizumab (Lucentis), a drug that is highly effective at preventing vision loss in intraocular neovascular disorders.[citation needed]

Education

Ferrara received his medical degree from the University of Catania, Italy, in , and joined Genentech in He did his postdoctoral research at University of California, San Francisco.[2]

Current research

At UC San Diego Moores Cancer Center, Ferrara, a member of the National Academy of Sciences since , serves as Senior Deputy Director for Basic Science and is a Distinguished Professor of Pathology in the UC San Diego School of Medicine, where he will continue cancer drug research targeting angiogenesis.[citation needed] He is presently focusing on investigating mechanisms of tumor angiogenesis alternative to VEGF, in particular the role of factors produced by myeloid cells and fibroblasts in mediating resistance to VEGF inhibitors.[citation needed]

Selected honors and awards

For his VEGF discovery, he won a Lasker Award in [3] In , he was awarded the $3 million Breakthrough Prize in Life Sciences for his work.[4] He has received numerous other awards, including the General Motors Cancer Research Award (), the ASCO Science of Oncology Award (), the Pezcoller Foundation/AACR International Award (), the Dr.

Paul Janssen Award for Biomedical Research (), and The Economist's Innovation Award for bioscience in [citation needed]Grand Prix scientifique de la Fondation Lefoulon-Delalande in [5]

In September , Ferrara was awarded the António Champalimaud Vision Award, awarded by the Champalimaud Foundation.[6]

, Keio Medical Science Prize.[7]

References

Breakthrough Prize laureates

Mathematics
Fundamental
physics
  • Nima Arkani-Hamed, Alan Guth, Alexei Kitaev, Maxim Kontsevich, Andrei Linde, Juan Maldacena, Nathan Seiberg, Ashoke Sen, Edward Witten ()
  • Special: Stephen Hawking, Peter Jenni, Fabiola Gianotti (ATLAS), Michel Della Negra, Tejinder Virdee, Guido Tonelli, Joseph Incandela (CMS) and Lyn Evans (LHC) ()
  • Alexander Polyakov ()
  • Michael Green and John Henry Schwarz ()
  • Saul Perlmutter and members of the Supernova Cosmology Project; Brian Schmidt, Adam Riess and members of the High-Z Supernova Team ()
  • Special: Ronald Drever, Kip Thorne, Rainer Weiss and contributors to LIGO project ()
  • Yifang Wang, Kam-Biu Luk and the Daya Bay team, Atsuto Suzuki and the KamLAND team, Kōichirō Nishikawa and the K2K / T2K team, Arthur B.

    McDonald and the Sudbury Neutrino Observatory team, Takaaki Kajita and Yōichirō Suzuki and the Super-Kamiokande team ()

  • Joseph Polchinski, Andrew Strominger, Cumrun Vafa ()
  • Charles L. Bennett, Gary Hinshaw, Norman Jarosik, Lyman Page Jr., David Spergel ()
  • Special: Jocelyn Bell Burnell ()
  • Charles Kane and Eugene Mele ()
  • Special: Sergio Ferrara, Daniel Z.

    Freedman, Peter van Nieuwenhuizen ()

  • The Event Horizon Telescope Collaboration ()
  • Eric Adelberger, Jens H. Gundlach and Blayne Heckel ()
  • Special: Steven Weinberg ()
  • Hidetoshi Katori and Jun Ye ()
  • Charles H. Bennett, Gilles Brassard, David Deutsch, Peter W. Shor ()
  • John Cardy and Alexander Zamolodchikov ()
Life sciences
  • Cornelia Bargmann, David Botstein, Lewis C.

    Cantley, Hans Clevers, Titia de Lange, Napoleone Ferrara, Eric Lander, Charles Sawyers, Robert Weinberg, Shinya Yamanaka and Bert Vogelstein ()

  • James P. Allison, Mahlon DeLong, Michael N. Hall, Robert S. Langer, Richard P. Lifton and Alexander Varshavsky ()
  • Alim Louis Benabid, Charles David Allis, Victor Ambros, Gary Ruvkun, Jennifer Doudna and Emmanuelle Charpentier ()
  • Edward Boyden, Karl Deisseroth, John Hardy, Helen Hobbs and Svante Pääbo ()
  • Stephen J.

    Elledge, Harry F. Noller, Roeland Nusse, Yoshinori Ohsumi, Huda Zoghbi ()

  • Joanne Chory, Peter Walter, Kazutoshi Mori, Kim Nasmyth, Don W. Cleveland ()
  • C. Frank Bennett and Adrian R. Krainer, Angelika Amon, Xiaowei Zhuang, Zhijian Chen ()
  • Jeffrey M. Friedman, Franz-Ulrich Hartl, Arthur L. Horwich, David Julius, Virginia Man-Yee Lee ()
  • David Baker, Catherine Dulac, Dennis Lo, Richard J.

    Youle&#;[de] ()

  • Jeffery W. Kelly, Katalin Karikó, Drew Weissman, Shankar Balasubramanian, David Klenerman and Pascal Mayer ()
  • Clifford P. Brangwynne, Anthony A. Hyman, Demis Hassabis, John Jumper, Emmanuel Mignot, Masashi Yanagisawa ()
  • Carl June, Michel Sadelain, Sabine Hadida, Paul Negulescu, Fredrick Van Goor, Thomas Gasser, Ellen Sidransky and Andrew Singleton ()